Victory Capital Management Inc. Has $950,000 Stock Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Victory Capital Management Inc. raised its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 164.9% in the third quarter, Holdings Channel.com reports. The firm owned 51,577 shares of the company’s stock after buying an additional 32,108 shares during the period. Victory Capital Management Inc.’s holdings in Hims & Hers Health were worth $950,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in HIMS. Vanguard Group Inc. boosted its stake in Hims & Hers Health by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock valued at $221,379,000 after purchasing an additional 136,907 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Hims & Hers Health by 239.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 168,427 shares of the company’s stock valued at $2,606,000 after purchasing an additional 118,848 shares during the last quarter. Strategic Wealth Partners Ltd. acquired a new position in Hims & Hers Health during the 1st quarter valued at about $839,000. Virtu Financial LLC acquired a new position in Hims & Hers Health during the 1st quarter valued at about $638,000. Finally, Farallon Capital Management LLC boosted its stake in shares of Hims & Hers Health by 3,890.5% in the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after buying an additional 1,634,000 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insider Buying and Selling at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 11,609 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.60, for a total value of $169,491.40. Following the transaction, the chief financial officer now owns 181,469 shares of the company’s stock, valued at approximately $2,649,447.40. This represents a 6.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Soleil Boughton sold 2,343 shares of the company’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $29.90, for a total transaction of $70,055.70. Following the completion of the transaction, the insider now directly owns 165,254 shares in the company, valued at approximately $4,941,094.60. The trade was a 1.40 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,153,519 shares of company stock valued at $24,486,721 in the last 90 days. 17.71% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

HIMS has been the topic of a number of research analyst reports. Canaccord Genuity Group boosted their target price on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Imperial Capital downgraded Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Piper Sandler restated a “neutral” rating and issued a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. TD Cowen restated a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Finally, Needham & Company LLC initiated coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They issued a “buy” rating and a $24.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $20.71.

Hims & Hers Health Price Performance

Shares of HIMS stock opened at $30.35 on Thursday. The company’s fifty day simple moving average is $21.14 and its two-hundred day simple moving average is $19.57. Hims & Hers Health, Inc. has a 1 year low of $8.09 and a 1 year high of $35.02. The stock has a market capitalization of $6.63 billion, a price-to-earnings ratio of 68.96 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. During the same quarter in the previous year, the firm posted ($0.04) EPS. The business’s revenue for the quarter was up 77.1% compared to the same quarter last year. Equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.